US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Gyre Therapeutics

6.91

-0.1100-1.57%

Post-market: 6.910.00000.00%19:19 EDT

Volume:66.00K

Turnover:458.46K

Market Cap:770.53M

PE:-36.31

High:7.12

Open:7.08

Low:6.86

Close:7.02

52wk High:9.42

52wk Low:5.44

Shares:111.51M

Float Shares:35.93M

Volume Ratio:1.13

T/O Rate:0.18%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.1903

EPS(LYR):0.0225

ROE:-17.44%

ROA:-5.42%

PB:7.14

PE(LYR):307.33

Loading ...

Overview Company News Filings

Gyre Therapeutics shareholders elect directors at annual meeting

Top Executive Makes Notable Move With Gyre Therapeutics Stock

Gyre COO Weiguo Ye disposes of 2,800 common shares for $17,276

Gyre Therapeutics COO Ye Weiguo sells USD 129,295 of common shares

Top Executive’s Bold Move at Gyre Therapeutics Stirs Investor Buzz

Gyre Therapeutics COO Ye Weiguo disposes of USD 217,732 of common shares

Gyre Therapeutics Updates Post-Cullgen Acquisition Growth Strategy

Gyre Therapeutics publishes corporate presentation on fibrosis, inflammatory disease and cancer pipeline

Gyre Therapeutics COO Weiguo Ye sells 7,500 common shares for $45,690.35

Gyre COO Ye Weiguo disposes of 22,220 shares worth $136,653

Gyre COO Ye Weiguo sells USD 59,833 Gyre Therapeutics shares

Gyre COO Weiguo Ye disposes 28,680 shares for $193,510.3

Gyre Therapeutics Highlights Cullgen Acquisition and Pipeline Expansion

Gyre Therapeutics announces China NMPA acceptance of F351 NDA

China NMPA accepts Gyre NDA for hydronidone in hepatitis B liver fibrosis

Gyre Therapeutics Announces Nmpa Acceptance of New Drug Application for F351 (Hydronidone) for Chb-Induced Liver Fibrosis Treatment

THOMSON REUTERS

Gyre Therapeutics: Plans to File Ind Application in U.S. by 2026 End; IF Ind Becomes Effective, to Initiate Phase 2 Clinical Trial

THOMSON REUTERS

Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment

Noble Financial Sticks to Their Buy Rating for Gyre Therapeutics (GYRE)

Gyre Therapeutics reports Q1 EPS (10c) vs. 0c last year

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/GYRE/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GYRE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GYRE\",,,,,undefined,":{"symbol":"GYRE","market":"US","secType":"STK","nameCN":"Gyre Therapeutics","latestPrice":6.91,"timestamp":1787342400000,"preClose":7.02,"halted":0,"volume":65999,"hourTrading":{"tag":"盘后","latestPrice":6.91,"preClose":6.91,"latestTime":"19:19 EDT","volume":34,"amount":234.94,"timestamp":1787354341013,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.01566951566951559,"floatShares":35934500,"shares":111509800,"eps":-0.190324,"marketStatus":"Market Closed","change":-0.11,"latestTime":"08-21 16:00:00 EDT","open":7.08,"high":7.12,"low":6.86,"amount":458460.93151699996,"amplitude":0.037037,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.190324,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":7.02,"preHourTrading":{"tag":"盘前","latestPrice":7.02,"preClose":7.02,"latestTime":"09:12 EDT","volume":6,"amount":42.220001999999994,"timestamp":1787317923389,"change":0,"changeRate":0,"amplitude":0.002849},"postHourTrading":{"tag":"盘后","latestPrice":6.91,"preClose":6.91,"latestTime":"19:19 EDT","volume":34,"amount":234.94,"timestamp":1787354341013,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.126770421784978,"impliedVol":0.3599,"impliedVolPercentile":0.1554},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GYRE\",,,,,undefined,":{"symbol":"GYRE","floatShares":35934500,"roa":"-5.42%","roe":"-17.44%","lyrEps":0.022484,"volumeRatio":1.126770421784978,"shares":111509800,"dividePrice":0,"high":7.12,"amplitude":0.037037,"preClose":7.02,"low":6.86,"week52Low":5.44,"pbRate":"7.14","psRate":"7.02","week52High":9.42,"institutionHeld":0.1087,"latestPrice":6.91,"eps":-0.190324,"divideRate":0,"volume":65999,"delay":0,"ttmEps":-0.190324,"open":7.08,"prevYearClose":7.06,"prevWeekClose":6.68,"prevMonthClose":5.75,"prevQuarterClose":6.59,"fiveDayClose":6.68,"twentyDayClose":5.94,"sixtyDayClose":5.92},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GYRE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-07","symbol":"GYRE","fiscalQuarterEnding":"2026/06","expectedEps":-0.08,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786075200000,"reportTimeType":"pre","actualEps":-0.12},{"market":"US","date":"2026-05-07","symbol":"GYRE","fiscalQuarterEnding":"2026/03","expectedEps":-0.06,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778126400000,"reportTimeType":"pre","actualEps":-0.08},{"market":"US","date":"2026-03-12","symbol":"GYRE","fiscalQuarterEnding":"2025/12","expectedEps":0.08,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1773288000000,"reportTimeType":"pre","actualEps":0.04},{"market":"US","date":"2025-11-07","symbol":"GYRE","fiscalQuarterEnding":"2025/09","expectedEps":0.05,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1762491600000,"reportTimeType":"pre","actualEps":0.05},{"market":"US","date":"2025-08-11","symbol":"GYRE","fiscalQuarterEnding":"2025/06","expectedEps":0.03,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1754884800000,"reportTimeType":"post","actualEps":0.02}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GYRE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GYRE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":3,"updateTime":1760155200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/GYRE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"GYRE","date":"2026-08-21","current":-36.306509,"percent":0.172117,"low":-11548.718266,"twenty":-31.698577,"median":-9.517342,"eighty":116.303482,"high":193.429414,"avg":-547.030306,"sd":2284.816782,"marketCap":744357016},"quantilePoints":[{"date":"2024-04-05","current":-15.607876,"twenty":-15.830217,"median":-15.617068,"eighty":-15.398378,"marketCap":1450486717},{"date":"2024-04-12","current":-31.76291,"twenty":-32.589325,"median":-21.429161,"eighty":-15.61523,"marketCap":1405212396},{"date":"2024-04-19","current":-29.754799,"twenty":-32.477335,"median":-30.585076,"eighty":-15.742078,"marketCap":1316372220},{"date":"2024-04-26","current":-31.531205,"twenty":-31.948274,"median":-30.797472,"eighty":-16.000876,"marketCap":1394961607},{"date":"2024-05-03","current":-27.239192,"twenty":-31.948274,"median":-30.778163,"eighty":-24.631989,"marketCap":1205080075},{"date":"2024-05-10","current":-14.851474,"twenty":-31.774495,"median":-30.223912,"eighty":-24.631989,"marketCap":1301657414},{"date":"2024-05-17","current":-14.909982,"twenty":-31.744918,"median":-29.754799,"eighty":-15.561911,"marketCap":1306785414},{"date":"2024-05-24","current":-12.302842,"twenty":-31.573048,"median":-28.630129,"eighty":-14.89828,"marketCap":1078282562},{"date":"2024-05-31","current":-8605.737804,"twenty":-32.075712,"median":-29.501562,"eighty":-15.108912,"marketCap":890160307},{"date":"2024-06-07","current":-8895.075775,"twenty":-32.90985,"median":-30.136978,"eighty":-15.311743,"marketCap":920088848},{"date":"2024-06-14","current":-9126.546144,"twenty":-8519.763095,"median":-30.585076,"eighty":-15.366351,"marketCap":944031680},{"date":"2024-06-21","current":-8961.210165,"twenty":-8885.155616,"median":-30.816781,"eighty":-15.424018,"marketCap":926929657},{"date":"2024-06-28","current":-8175.864257,"twenty":-8865.315298,"median":-30.894016,"eighty":-15.515947,"marketCap":845695047},{"date":"2024-07-05","current":-9688.68848,"twenty":-8961.210165,"median":-31.531205,"eighty":-15.611553,"marketCap":1002178559},{"date":"2024-07-12","current":-10424.433593,"twenty":-9151.346542,"median":-31.791873,"eighty":-15.679573,"marketCap":1078282562},{"date":"2024-07-15","current":-11094.044316,"twenty":-9210.867496,"median":-31.820836,"eighty":-15.710825,"marketCap":1147545756},{"date":"2024-08-02","current":-11548.718266,"twenty":-9298.495565,"median":-32.139431,"eighty":-15.742078,"marketCap":1194576320},{"date":"2024-08-09","current":-8374.267436,"twenty":-9189.373818,"median":-32.728348,"eighty":-16.000876,"marketCap":866217475},{"date":"2024-08-16","current":-10.635127,"twenty":-9134.812943,"median":-32.641458,"eighty":-15.61523,"marketCap":914301855},{"date":"2024-08-23","current":-11.421808,"twenty":-9126.546144,"median":-31.820836,"eighty":-15.175222,"marketCap":981932798},{"date":"2024-08-30","current":-13.672312,"twenty":-9020.73112,"median":-31.635813,"eighty":-14.375603,"marketCap":1175408659},{"date":"2024-09-06","current":-11.770337,"twenty":-8974.437045,"median":-30.942288,"eighty":-13.816505,"marketCap":1011895874},{"date":"2024-09-13","current":-14.920484,"twenty":-8961.210165,"median":-30.778163,"eighty":-13.696211,"marketCap":1282714046},{"date":"2024-09-20","current":-15.572509,"twenty":-8941.369845,"median":-30.223912,"eighty":-13.816505,"marketCap":1338768556},{"date":"2024-09-27","current":-13.909847,"twenty":-8923.182886,"median":-29.754799,"eighty":-13.90034,"marketCap":1195829555},{"date":"2024-10-04","current":-13.312158,"twenty":-8919.876167,"median":-28.630129,"eighty":-13.654308,"marketCap":1144446254},{"date":"2024-10-11","current":-12.327984,"twenty":-8904.995932,"median":-26.800559,"eighty":-13.325198,"marketCap":1059836795},{"date":"2024-10-18","current":-15.235629,"twenty":-8865.315298,"median":-15.915547,"eighty":-13.300875,"marketCap":1309807059},{"date":"2024-10-25","current":-15.300832,"twenty":-8830.594739,"median":-15.607876,"eighty":-13.325198,"marketCap":1315412510},{"date":"2024-10-31","current":-15.985457,"twenty":-8804.140979,"median":-15.617068,"eighty":-13.405529,"marketCap":1374269746},{"date":"2024-11-08","current":-16.365804,"twenty":-8779.340581,"median":-15.748988,"eighty":-13.558712,"marketCap":1406968211},{"date":"2024-11-15","current":-13.372591,"twenty":-8709.89947,"median":-15.77333,"eighty":-13.558712,"marketCap":1187780244},{"date":"2024-11-22","current":-11.353175,"twenty":-8602.431085,"median":-15.627389,"eighty":-13.295234,"marketCap":1008411696},{"date":"2024-11-29","current":-12.087508,"twenty":-8556.137012,"median":-15.590193,"eighty":-13.126615,"marketCap":1073636622},{"date":"2024-12-06","current":-10.111572,"twenty":-8387.494312,"median":-15.378053,"eighty":-12.781935,"marketCap":898130076},{"date":"2024-12-13","current":-9.449706,"twenty":-8374.267436,"median":-15.329691,"eighty":-12.475931,"marketCap":839341820},{"date":"2024-12-20","current":-10.299987,"twenty":-8344.506959,"median":-15.279098,"eighty":-12.329976,"marketCap":914865419},{"date":"2024-12-27","current":-12.686569,"twenty":-8225.465052,"median":-15.246496,"eighty":-12.302842,"marketCap":1126846431},{"date":"2025-01-03","current":-11.594732,"twenty":-8192.397854,"median":-15.235629,"eighty":-12.152426,"marketCap":1029867264},{"date":"2025-01-10","current":-9.29511,"twenty":-8179.170976,"median":-15.105225,"eighty":-11.98162,"marketCap":825610256},{"date":"2025-01-17","current":-10.435259,"twenty":-3290.168076,"median":-14.953086,"eighty":-11.68749,"marketCap":926880537},{"date":"2025-01-24","current":-10.242013,"twenty":-32.95233,"median":-14.893499,"eighty":-11.536758,"marketCap":909716083},{"date":"2025-01-31","current":-11.111618,"twenty":-32.786274,"median":-14.681409,"eighty":-11.380628,"marketCap":986956128},{"date":"2025-02-07","current":-12.319402,"twenty":-32.658836,"median":-14.539395,"eighty":-11.347378,"marketCap":1094233968},{"date":"2025-02-14","current":-11.382162,"twenty":-32.515952,"median":-14.451664,"eighty":-11.279742,"marketCap":1010986364},{"date":"2025-02-21","current":-12.135819,"twenty":-32.330588,"median":-14.072853,"eighty":-11.345445,"marketCap":1077927736},{"date":"2025-02-28","current":-10.90871,"twenty":-31.809251,"median":-13.976035,"eighty":-11.179254,"marketCap":968933450},{"date":"2025-03-07","current":-10.338636,"twenty":-31.758412,"median":-13.909847,"eighty":-11.12128,"marketCap":918298310},{"date":"2025-03-14","current":-11.556083,"twenty":-31.698577,"median":-13.789262,"eighty":-11.11355,"marketCap":1026434373},{"date":"2025-03-21","current":79.165838,"twenty":-31.423076,"median":-13.627303,"eighty":-11.045914,"marketCap":956719157},{"date":"2025-03-28","current":70.412668,"twenty":-30.971251,"median":-13.353241,"eighty":-10.90871,"marketCap":850937097},{"date":"2025-04-04","current":52.673943,"twenty":-30.878569,"median":-13.283951,"eighty":-10.748316,"marketCap":636564605},{"date":"2025-04-11","current":56.469566,"twenty":-30.809057,"median":-13.129602,"eighty":-10.622099,"marketCap":682434702},{"date":"2025-04-17","current":61.504575,"twenty":-30.778163,"median":-12.849861,"eighty":-10.560868,"marketCap":743282789},{"date":"2025-04-25","current":70.645053,"twenty":-30.585076,"median":-12.780906,"eighty":-10.377285,"marketCap":853745471},{"date":"2025-05-02","current":72.449806,"twenty":-30.310846,"median":-12.626921,"eighty":-10.338636,"marketCap":875555902},{"date":"2025-05-09","current":73.535777,"twenty":-30.136978,"median":-12.473999,"eighty":-10.164715,"marketCap":888679866},{"date":"2025-05-16","current":132.923099,"twenty":-29.947887,"median":-12.417259,"eighty":-9.938068,"marketCap":963825388},{"date":"2025-05-23","current":136.20365,"twenty":-29.754799,"median":-12.327984,"eighty":-9.652614,"marketCap":987612669},{"date":"2025-05-30","current":117.840031,"twenty":-29.349619,"median":-12.308068,"eighty":-9.440044,"marketCap":854458067},{"date":"2025-06-06","current":99.64599,"twenty":-28.753768,"median":-12.251767,"eighty":50.257139,"marketCap":722533070},{"date":"2025-06-13","current":100.896253,"twenty":-28.630129,"median":-12.168656,"eighty":56.159719,"marketCap":731598729},{"date":"2025-06-20","current":104.146938,"twenty":-27.795567,"median":-12.087508,"eighty":59.335648,"marketCap":755169444},{"date":"2025-06-27","current":92.269436,"twenty":-26.976012,"median":-11.969641,"eighty":62.92987,"marketCap":669045678},{"date":"2025-07-03","current":101.646411,"twenty":-26.790554,"median":-11.75017,"eighty":66.71,"marketCap":737038125},{"date":"2025-07-11","current":97.645568,"twenty":-23.367997,"median":-11.701017,"eighty":68.524795,"marketCap":708028014},{"date":"2025-07-18","current":92.394462,"twenty":-17.913275,"median":-11.686523,"eighty":70.505622,"marketCap":669952244},{"date":"2025-07-25","current":92.269436,"twenty":-17.24169,"median":-11.594732,"eighty":71.634434,"marketCap":669045678},{"date":"2025-08-01","current":88.143567,"twenty":-16.863516,"median":-11.531927,"eighty":73.525921,"marketCap":639129001},{"date":"2025-08-08","current":90.018962,"twenty":-16.53533,"median":-11.498109,"eighty":77.782591,"marketCap":652727491},{"date":"2025-08-15","current":179.246974,"twenty":-16.326683,"median":-11.42614,"eighty":87.268382,"marketCap":746563646},{"date":"2025-08-22","current":164.643977,"twenty":-16.268001,"median":-11.353175,"eighty":89.218793,"marketCap":685742166},{"date":"2025-08-29","current":180.563196,"twenty":-16.183906,"median":-11.256552,"eighty":90.29402,"marketCap":752045713},{"date":"2025-09-05","current":165.298192,"twenty":-16.049822,"median":-11.217903,"eighty":91.769331,"marketCap":688466969},{"date":"2025-09-12","current":177.074053,"twenty":-16.011538,"median":-11.179254,"eighty":92.594504,"marketCap":737513429},{"date":"2025-09-19","current":167.696978,"twenty":-15.943032,"median":-11.12128,"eighty":93.569709,"marketCap":698457915},{"date":"2025-09-26","current":158.974119,"twenty":-15.763593,"median":-11.111618,"eighty":95.145041,"marketCap":662127204},{"date":"2025-10-03","current":163.989763,"twenty":-15.70726,"median":-11.048813,"eighty":96.920416,"marketCap":683017363},{"date":"2025-10-10","current":155.921118,"twenty":-15.633582,"median":-10.966684,"eighty":99.846032,"marketCap":649411455},{"date":"2025-10-17","current":190.594485,"twenty":-15.61523,"median":-10.876478,"eighty":100.896253,"marketCap":793826030},{"date":"2025-10-24","current":179.472839,"twenty":-15.600803,"median":-10.763776,"eighty":101.646411,"marketCap":747504374},{"date":"2025-10-31","current":166.824692,"twenty":-15.546428,"median":-10.691308,"eighty":105.447211,"marketCap":694824844},{"date":"2025-11-07","current":160.064476,"twenty":-15.429294,"median":-10.618842,"eighty":111.643728,"marketCap":666668543},{"date":"2025-11-14","current":110.418625,"twenty":-15.377823,"median":-10.570531,"eighty":112.102687,"marketCap":734394278},{"date":"2025-11-21","current":102.355879,"twenty":-15.373231,"median":-10.435259,"eighty":110.254637,"marketCap":680768953},{"date":"2025-11-28","current":105.908954,"twenty":-15.35855,"median":-10.377285,"eighty":109.598685,"marketCap":704400452},{"date":"2025-12-05","current":107.958805,"twenty":-15.300832,"median":-10.338636,"eighty":109.462028,"marketCap":718034009},{"date":"2025-12-12","current":107.548834,"twenty":-15.279098,"median":-10.299987,"eighty":109.871999,"marketCap":715307298},{"date":"2025-12-19","current":100.442685,"twenty":-15.279098,"median":-10.179208,"eighty":109.598685,"marketCap":668044300},{"date":"2025-12-26","current":98.256178,"twenty":-15.261711,"median":-10.046352,"eighty":109.489359,"marketCap":653501839},{"date":"2026-01-02","current":96.479641,"twenty":-15.250843,"median":-9.954769,"eighty":109.29804,"marketCap":641686089},{"date":"2026-01-09","current":103.449133,"twenty":-15.243518,"median":-9.652614,"eighty":109.106721,"marketCap":688040184},{"date":"2026-01-16","current":105.22567,"twenty":-15.23799,"median":-9.652614,"eighty":108.560094,"marketCap":699855933},{"date":"2026-01-23","current":110.008655,"twenty":-15.222589,"median":-9.517342,"eighty":109.134052,"marketCap":731667567},{"date":"2026-01-30","current":112.195163,"twenty":-15.163907,"median":-9.314435,"eighty":109.544022,"marketCap":746210028},{"date":"2026-02-06","current":102.629193,"twenty":-15.092184,"median":51.163441,"eighty":109.680679,"marketCap":682586761},{"date":"2026-02-13","current":106.865551,"twenty":-15.037849,"median":54.920332,"eighty":109.544022,"marketCap":710762779},{"date":"2026-02-20","current":115.064954,"twenty":-14.972646,"median":56.469566,"eighty":109.844668,"marketCap":765297008},{"date":"2026-02-27","current":116.431521,"twenty":-14.918384,"median":59.41311,"eighty":110.555282,"marketCap":774386046},{"date":"2026-03-06","current":107.002208,"twenty":-14.903389,"median":60.420111,"eighty":111.484548,"marketCap":711671683},{"date":"2026-03-13","current":141.117848,"twenty":-14.871908,"median":65.067812,"eighty":112.058506,"marketCap":709399423},{"date":"2026-03-20","current":123.520041,"twenty":-14.817461,"median":66.926893,"eighty":112.457994,"marketCap":620935247},{"date":"2026-03-27","current":127.879572,"twenty":-14.672715,"median":68.213723,"eighty":113.15176,"marketCap":642850609},{"date":"2026-04-02","current":131.330867,"twenty":-14.637941,"median":68.717439,"eighty":113.9717,"marketCap":660200270},{"date":"2026-04-10","current":131.512514,"twenty":-14.560386,"median":70.412668,"eighty":115.791328,"marketCap":661113410},{"date":"2026-04-17","current":143.501224,"twenty":-14.518403,"median":70.916169,"eighty":118.208058,"marketCap":721380655},{"date":"2026-04-24","current":135.145457,"twenty":-14.464068,"median":71.829251,"eighty":123.520041,"marketCap":679376212},{"date":"2026-05-01","current":139.504988,"twenty":-14.451664,"median":72.980471,"eighty":126.240493,"marketCap":701291573},{"date":"2026-05-08","current":-107.788052,"twenty":-14.451664,"median":73.535777,"eighty":127.334631,"marketCap":685747587},{"date":"2026-05-15","current":-100.534989,"twenty":-14.637941,"median":72.372236,"eighty":126.808829,"marketCap":639603601},{"date":"2026-05-22","current":-88.758033,"twenty":-14.909982,"median":71.342209,"eighty":126.608042,"marketCap":564678607},{"date":"2026-05-29","current":-82.438691,"twenty":-15.079143,"median":70.645053,"eighty":126.314003,"marketCap":524474952},{"date":"2026-06-05","current":-88.901655,"twenty":-15.242525,"median":70.38405,"eighty":126.098579,"marketCap":565592327},{"date":"2026-06-12","current":-87.034576,"twenty":-15.283445,"median":68.648906,"eighty":126.010611,"marketCap":553713974},{"date":"2026-06-18","current":-87.321819,"twenty":-15.377362,"median":68.088818,"eighty":124.946974,"marketCap":555541413},{"date":"2026-06-26","current":-89.47614,"twenty":-15.611553,"median":66.655777,"eighty":123.810677,"marketCap":569247204},{"date":"2026-07-02","current":-93.641161,"twenty":-15.753857,"median":65.067812,"eighty":123.374723,"marketCap":595745068},{"date":"2026-07-10","current":-120.215892,"twenty":-16.183906,"median":60.420111,"eighty":122.720794,"marketCap":764813504},{"date":"2026-07-17","current":-112.505251,"twenty":-16.863516,"median":59.41311,"eighty":121.124631,"marketCap":715758410},{"date":"2026-07-24","current":-105.320337,"twenty":-26.790554,"median":56.469566,"eighty":119.109992,"marketCap":670047982},{"date":"2026-07-31","current":-101.8155,"twenty":-28.630129,"median":54.920332,"eighty":118.134453,"marketCap":647750212},{"date":"2026-08-07","current":-112.154768,"twenty":-30.09916,"median":51.163441,"eighty":117.790204,"marketCap":713528633},{"date":"2026-08-14","current":-32.674966,"twenty":-30.809057,"median":-9.314435,"eighty":117.359023,"marketCap":693460810},{"date":"2026-08-21","current":-35.073129,"twenty":-31.698577,"median":-9.517342,"eighty":116.303482,"marketCap":744357016}],"updateTime":1787500335863},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GYRE\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2643756521","title":"Gyre Therapeutics shareholders elect directors at annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2643756521","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643756521?lang=en_us&edition=fundamental","pubTime":"2026-06-16 18:31","pubTimestamp":1781605889,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics held its annual stockholders meeting on June 10, 2026.Stockholders voted in favor of seating two Class II director nominees, with terms running through the 2029 annual meeting.Stockholders ratified Grant Thornton Zhitong Certified Public Accountants LLP as independent registered public accounting firm for 2026.Stockholders authorized issuance of common shares upon conversion of the Series B Convertible Preferred Stock; conversion itself was not reported as completed.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gyre Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Com","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nNDL5RfsjG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643780268","title":"Top Executive Makes Notable Move With Gyre Therapeutics Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2643780268","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643780268?lang=en_us&edition=fundamental","pubTime":"2026-06-16 10:10","pubTimestamp":1781575829,"startTime":"0","endTime":"0","summary":"New insider activity at Gyre Therapeutics ( ($GYRE) ) has taken place on June 15, 2026. Gyre Therapeutics’ Chief Operating Officer, Ye Weiguo, has ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/top-executive-makes-notable-move-with-gyre-therapeutics-stock-insider-trading-news-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/top-executive-makes-notable-move-with-gyre-therapeutics-stock-insider-trading-news-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643858717","title":"Gyre COO Weiguo Ye disposes of 2,800 common shares for $17,276","url":"https://stock-news.laohu8.com/highlight/detail?id=2643858717","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643858717?lang=en_us&edition=fundamental","pubTime":"2026-06-16 04:01","pubTimestamp":1781553715,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics COO Weiguo Ye exercised stock options for 2,800 common shares at $0.75 on June 11, 2026.Ye sold 2,800 common shares at $6.17 the same day, leaving direct ownership of 700,000 shares.He reported 838,701 stock options outstanding following the transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gyre Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 15, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nNDL5yCWR2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Gyre COO Weiguo Ye disposes of 2,800 common shares for $17,276","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642231618","title":"Gyre Therapeutics COO Ye Weiguo sells USD 129,295 of common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2642231618","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642231618?lang=en_us&edition=fundamental","pubTime":"2026-06-12 04:01","pubTimestamp":1781208119,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics COO Ye Weiguo sold 20,918 common shares on June 9-10, 2026 at weighted-average prices of $6.14-$6.21.Sales followed the exercise of stock options for the same 20,918 shares at $0.75 per share.Ye’s direct common stock holdings were unchanged at 700,000 shares following the transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gyre Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 11, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nNDL3WyWsZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Gyre Therapeutics COO Ye Weiguo sells USD 129,295 of common shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642554434","title":"Top Executive’s Bold Move at Gyre Therapeutics Stirs Investor Buzz","url":"https://stock-news.laohu8.com/highlight/detail?id=2642554434","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642554434?lang=en_us&edition=fundamental","pubTime":"2026-06-09 10:10","pubTimestamp":1780971053,"startTime":"0","endTime":"0","summary":"New insider activity at Gyre Therapeutics ( ($GYRE) ) has taken place on June 8, 2026. Gyre Therapeutics has seen notable insider activity as Chief...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/top-executives-bold-move-at-gyre-therapeutics-stirs-investor-buzz-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/top-executives-bold-move-at-gyre-therapeutics-stirs-investor-buzz-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","GYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642431802","title":"Gyre Therapeutics COO Ye Weiguo disposes of USD 217,732 of common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2642431802","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642431802?lang=en_us&edition=fundamental","pubTime":"2026-06-09 04:02","pubTimestamp":1780948921,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics COO Ye Weiguo exercised stock options on June 4-5, acquiring 34,976 common shares at $0.75.He sold 34,976 common shares those same days at weighted-average prices of $6.13 and $6.4.His direct holdings were unchanged at 700,000 common shares following the transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gyre Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 08, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nNDLcc2s5D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Gyre Therapeutics COO Ye Weiguo disposes of USD 217,732 of common shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640125929","title":"Gyre Therapeutics Updates Post-Cullgen Acquisition Growth Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2640125929","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640125929?lang=en_us&edition=fundamental","pubTime":"2026-06-02 18:32","pubTimestamp":1780396364,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics ( ($GYRE) ) has issued an announcement. On June 1, 2026, Gyre Therapeutics released an updated corporate presentation outlining i...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gyre-therapeutics-updates-post-cullgen-acquisition-growth-strategy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gyre-therapeutics-updates-post-cullgen-acquisition-growth-strategy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","POST","GYRE","BK4212"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640984199","title":"Gyre Therapeutics publishes corporate presentation on fibrosis, inflammatory disease and cancer pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2640984199","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640984199?lang=en_us&edition=fundamental","pubTime":"2026-06-02 08:07","pubTimestamp":1780358822,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics outlined a post-Cullgen strategy to use China operations to accelerate discovery, early validation, manufacturing, development, commercialization.F351  CHB-associated liver fibrosis Phase 3 met the primary endpoint; fibrosis regression at Week 52 was 52.85% vs 29.84% .Key secondary endpoint met; inflammation improvement without fibrosis progression was 49.57% vs 34.82% .F351 NDA accepted by China’s NMPA in May 2026; U.S. IND filed for MASH with Phase 2 start anticipated in 2027.ETUARY  positioned as a market-leading antifibrotic franchise with planned line extensions including pneumoconiosis, radiation-induced lung injury.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gyre Therapeutics Inc. published the original con","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDL487M9W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638355686","title":"Gyre Therapeutics COO Weiguo Ye sells 7,500 common shares for $45,690.35","url":"https://stock-news.laohu8.com/highlight/detail?id=2638355686","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638355686?lang=en_us&edition=fundamental","pubTime":"2026-05-28 04:02","pubTimestamp":1779912131,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics COO Weiguo Ye sold 7,500 shares on May 22-26 at about $6.09 a share.Transactions followed option exercises for 7,500 shares at $0.75.Direct common stock holdings stayed at 700,000 shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gyre Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 27, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nNDL4rRV3m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Gyre Therapeutics COO Weiguo Ye sells 7,500 common shares for $45,690.35","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637523347","title":"Gyre COO Ye Weiguo disposes of 22,220 shares worth $136,653","url":"https://stock-news.laohu8.com/highlight/detail?id=2637523347","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637523347?lang=en_us&edition=fundamental","pubTime":"2026-05-23 06:20","pubTimestamp":1779488418,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics Chief Operating Officer Weiguo Ye sold 22,220 shares on May 20-21 at USD 6.15 per share, based on weighted average prices.The sales followed the exercise of stock options for 22,220 shares at USD 0.75 per share.Ye’s direct holding was unchanged at 700,000 shares following the transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gyre Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 22, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nNDLc6zmCt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Gyre COO Ye Weiguo disposes of 22,220 shares worth $136,653","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637788918","title":"Gyre COO Ye Weiguo sells USD 59,833 Gyre Therapeutics shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2637788918","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637788918?lang=en_us&edition=fundamental","pubTime":"2026-05-21 04:02","pubTimestamp":1779307341,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics Chief Operating Officer Weiguo Ye cut his direct stake to 700,000 shares through option exercises followed by same-day sales on May 18-19.Sold 9,320 shares at weighted-average prices of $6.62 and $6.37, according to the filing.Exercised options for 9,320 shares at $0.75 per share.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gyre Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 20, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260520:nNDL9QyWdL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Gyre COO Ye Weiguo sells USD 59,833 Gyre Therapeutics shares","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636006434","title":"Gyre COO Weiguo Ye disposes 28,680 shares for $193,510.3","url":"https://stock-news.laohu8.com/highlight/detail?id=2636006434","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636006434?lang=en_us&edition=fundamental","pubTime":"2026-05-19 04:02","pubTimestamp":1779134543,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics Chief Operating Officer Weiguo Ye sold 28,680 shares on May 14-15 at weighted average prices of $6.91 and $6.65.The sales followed option exercises for the same number of shares at $0.75.Ye ended May 15 with 700,000 shares of common stock beneficially owned.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gyre Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 18, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nNDL4vLXPZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Gyre COO Weiguo Ye disposes 28,680 shares for $193,510.3","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635372272","title":"Gyre Therapeutics Highlights Cullgen Acquisition and Pipeline Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2635372272","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635372272?lang=en_us&edition=fundamental","pubTime":"2026-05-15 07:26","pubTimestamp":1778801194,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics ( ($GYRE) ) has issued an announcement. On May 15, 2026, Gyre Therapeutics planned to present a detailed corporate and scientific...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gyre-therapeutics-highlights-cullgen-acquisition-and-pipeline-expansion?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gyre-therapeutics-highlights-cullgen-acquisition-and-pipeline-expansion?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","GYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635022612","title":"Gyre Therapeutics announces China NMPA acceptance of F351 NDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2635022612","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635022612?lang=en_us&edition=fundamental","pubTime":"2026-05-13 06:36","pubTimestamp":1778625416,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics (GYRE) announced that the Center for Drug Evaluation, or CDE, of China’s National Medical Products Administration, or NMPA, has a...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gyre-therapeutics-announces-china-nmpa-acceptance-of-f351-nda-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gyre-therapeutics-announces-china-nmpa-acceptance-of-f351-nda-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635247158","title":"China NMPA accepts Gyre NDA for hydronidone in hepatitis B liver fibrosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2635247158","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635247158?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:09","pubTimestamp":1778616583,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics secured China NMPA acceptance of an NDA for F351  to treat chronic hepatitis B-induced liver fibrosis.NMPA previously granted priority review status for the application in March.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL2VPwty:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","IE00BN0W2T93.GBP","LU2210150020.SGD","IE00BKPKM429.USD","SG9999014039.USD","BK4588","SG9999014013.SGD","BK4112","LU2095319765.USD","SG9999014005.SGD","NDAQ","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU0314104364.USD","IE00BN0W2V16.EUR","GYRE","BK4585","IE00BGHQF748.EUR","IE00BN0W2W23.USD","LU2210149790.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635247538","title":"Gyre Therapeutics Announces Nmpa Acceptance of New Drug Application for F351 (Hydronidone) for Chb-Induced Liver Fibrosis Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2635247538","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635247538?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:05","pubTimestamp":1778616302,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nTUA1WRDYV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635235662","title":"Gyre Therapeutics: Plans to File Ind Application in U.S. by 2026 End; IF Ind Becomes Effective, to Initiate Phase 2 Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2635235662","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635235662?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:05","pubTimestamp":1778616302,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nTUA1WRDYV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635324053","title":"Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2635324053","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635324053?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:05","pubTimestamp":1778616300,"startTime":"0","endTime":"0","summary":"SAN DIEGO, May  12, 2026  (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (“Gyre”, “Gyre Therapeutics” or the “Company”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company with oper","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/12/3293396/0/en/Gyre-Therapeutics-Announces-NMPA-Acceptance-of-New-Drug-Application-for-F351-hydronidone-for-CHB-Induced-Liver-Fibrosis-Treatment.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCC","CDE","LU1223082196.USD","BK4021","DAC","BK4017","LU1223083913.SGD","IND","BK4139","LU1223082519.USD","CHB","GYRE","BK4006"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633451709","title":"Noble Financial Sticks to Their Buy Rating for Gyre Therapeutics (GYRE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633451709","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633451709?lang=en_us&edition=fundamental","pubTime":"2026-05-08 21:12","pubTimestamp":1778245967,"startTime":"0","endTime":"0","summary":"In a report released today, Robert LeBoyer from Noble Financial reiterated a Buy rating on Gyre Therapeutics, with a price target of $20.00. LeBoye...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/noble-financial-sticks-to-their-buy-rating-for-gyre-therapeutics-gyre-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/noble-financial-sticks-to-their-buy-rating-for-gyre-therapeutics-gyre-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GYRE","NBL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633712241","title":"Gyre Therapeutics reports Q1 EPS (10c) vs. 0c last year","url":"https://stock-news.laohu8.com/highlight/detail?id=2633712241","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633712241?lang=en_us&edition=fundamental","pubTime":"2026-05-08 00:59","pubTimestamp":1778173170,"startTime":"0","endTime":"0","summary":"Reports Q1 revenue $22.52M, consensus $31.61M. “Building on our successful pre-NDA meeting with China’s CDE at the beginning of the year, we are pa...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gyre-therapeutics-reports-q1-eps-10c-vs-0c-last-year-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gyre-therapeutics-reports-q1-eps-10c-vs-0c-last-year-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GYRE"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":2,"totalSize":82,"code":"91000000","status":"200"}]}}